SIBO Testing & Treatment: A Functional Medicine Approach
Quick Answer
Small Intestinal Bacterial Overgrowth (SIBO) is a digestive condition where excess bacteria colonise the small intestine, leading to fermentation, gas production, and impaired nutrient absorption. Effective long-term management may involve lactulose or glucose breath testing to identify hydrogen- or methane-dominant patterns, targeted antimicrobial therapy (such as rifaximin or herbal protocols), migrating motor complex support to reduce recurrence, and structured gut repair guided by a functional medicine practitioner (1,2).
At a Glance
- SIBO involves bacterial overgrowth in the small intestine and is associated with bloating, altered bowel habits, nutrient malabsorption, and fatigue.
- Hydrogen and methane breath testing, as outlined in the 2017 North American Consensus by Rezaie et al., is the standard non-invasive diagnostic method for SIBO.
- Herbal antimicrobials may be comparable in efficacy to rifaximin for SIBO treatment, according to a 2014 study by Chedid et al. in Global Advances in Health and Medicine.
- Impaired migrating motor complex (MMC) function is a recognised contributor to SIBO recurrence, as described by Deloose et al. in Nature Reviews Gastroenterology & Hepatology.
- Low-FODMAP diets may reduce symptoms but do not address the underlying bacterial overgrowth and are not recommended as long-term solutions.
What Is SIBO?
SIBO is defined by the presence of excessive bacteria in the small intestine, where microbial populations are normally maintained at low levels by gastric acid, bile salts, pancreatic enzymes, and the migrating motor complex (MMC). When these protective mechanisms are disrupted, bacteria from the large intestine can colonise the jejunum and ileum, leading to fermentation of carbohydrates, hydrogen and methane gas production, mucosal inflammation, and impaired absorption of key nutrients including iron, vitamin B12, and fat-soluble vitamins (3).
| Symptom | Possible Mechanism |
|---|---|
| Bloating and distension | Bacterial fermentation of carbohydrates producing hydrogen and methane gas |
| Diarrhoea | Bile salt deconjugation and osmotic effects associated with hydrogen-dominant SIBO |
| Constipation | Methane gas production by methanogenic archaea (e.g., Methanobrevibacter smithii) may slow intestinal transit |
| Fatigue | Nutrient malabsorption (iron, B12, folate) and systemic inflammatory signalling |
| Reflux | Increased intra-abdominal pressure from gas accumulation |
The Role of Breath Testing in Diagnosing SIBO
Breath testing remains the most widely validated non-invasive diagnostic tool for SIBO, with the 2017 North American Consensus guidelines by Rezaie et al. establishing standardised protocols for interpretation (4,5). After ingestion of a glucose or lactulose substrate, serial breath samples are collected over 90 to 180 minutes to measure hydrogen (H2) and methane (CH4) gases produced by bacterial fermentation in the small intestine.
| Gas Pattern | Dominant Organism | Typical Presentation |
|---|---|---|
| Hydrogen-dominant | Gram-negative facultative anaerobes (e.g., Escherichia coli, Klebsiella) | Diarrhoea, urgency, bloating |
| Methane-dominant (IMO) | Methanogenic archaea (e.g., Methanobrevibacter smithii) | Constipation, abdominal distension |
| Mixed (hydrogen + methane) | Combined bacterial and archaeal populations | Alternating bowel habits, complex symptom profile |
Breath testing also provides insight into symptom patterns and helps clinicians avoid unnecessary or poorly targeted treatments. Quigley et al. have emphasised the importance of proper test preparation, including a 24-hour preparatory diet, to maximise diagnostic accuracy (4).
Why Diet Alone Is Often Not Enough
Dietary restriction strategies such as the low-FODMAP protocol developed by researchers at Monash University can reduce bloating and gas by limiting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, but they do not directly address the underlying bacterial overgrowth (6). Staudacher et al. demonstrated in Gut (2017) that while FODMAP restriction may improve symptoms in irritable bowel syndrome (IBS), it can also reduce beneficial Bifidobacterium populations when maintained long-term.
Prolonged dietary restriction without addressing underlying contributors may negatively affect the gut microbiome and overall nutritional status.
Targeted Antimicrobial Treatment
Antimicrobial therapy guided by breath test results is the primary clinical intervention for confirmed SIBO, with treatment selection determined by gas type and symptom profile (7,8,9).
| Treatment Approach | Examples | Evidence Base |
|---|---|---|
| Prescription antibiotics (hydrogen-dominant) | Rifaximin (Xifaxan) | Pimentel et al., New England Journal of Medicine (2011) demonstrated efficacy in IBS without constipation (7) |
| Prescription antibiotics (methane-dominant) | Rifaximin combined with neomycin | Low et al., Digestive Diseases and Sciences (2010) showed benefit for methane-associated constipation (8) |
| Herbal antimicrobials | Berberine, oregano oil (Allimed, Dysbiocide, FC Cidal) | Chedid et al. (2014) found herbal protocols comparable to rifaximin in SIBO eradication rates (9) |
Personalisation is important, as individual responses and tolerance can vary. Antimicrobials are not intended to be used indefinitely.
Supporting Gut Motility to Reduce Recurrence Risk
Impaired gastrointestinal motility is one of the most significant contributors to SIBO recurrence, with Weinstock et al. (2021) reporting high relapse rates when motility dysfunction remains unaddressed (10,13). The migrating motor complex (MMC), described by Deloose et al. in Nature Reviews Gastroenterology & Hepatology, is a cyclical pattern of electromechanical activity that sweeps residual bacteria and debris from the small intestine during fasting periods.
| Motility Strategy | Mechanism |
|---|---|
| Prokinetic agents (pharmaceutical or nutritional) | Stimulate MMC Phase III contractions to clear small intestinal bacteria |
| Meal spacing (4-5 hours between meals) | Allows full MMC cycling, which is interrupted by food intake |
| Stress management and vagus nerve support | Supports parasympathetic tone via the gut-brain axis, which regulates MMC function |
| Regular physical movement | May support gastrointestinal transit and reduce bacterial stasis |
Assessment of stress physiology, including tools such as an adrenal function assessment, may be relevant for some individuals, given the well-established relationship between hypothalamic-pituitary-adrenal (HPA) axis dysregulation and impaired gut motility.
Gut Repair and Functional Support
Following antimicrobial therapy, structured gut repair aims to restore intestinal barrier integrity, support digestive enzyme activity, and rebalance the microbiome. Rao et al. (2020) highlighted the role of intestinal permeability in functional gastrointestinal disorders, supporting a phased repair approach (11).
| Repair Phase | Key Interventions | Rationale |
|---|---|---|
| Intestinal barrier support | L-glutamine, zinc carnosine | May support tight junction integrity and mucosal healing |
| Selective probiotic reintroduction | Strain-specific probiotics (e.g., Lactobacillus rhamnosus GG, Saccharomyces boulardii) | Didari et al. (2015) meta-analysis supports selective probiotic use in IBS-related conditions (12) |
| Digestive enzyme and bile support | Pancreatic enzymes, ox bile, betaine HCl | Addresses malabsorption and supports fat-soluble vitamin uptake |
In some cases, broader functional testing, such as organic acid testing or comprehensive microbiome analysis, may help identify metabolic or microbial factors influencing recovery.
When to Consider SIBO Testing
Clinical indicators that may warrant SIBO breath testing include persistent symptoms despite standard dietary or medical interventions, as noted by Ford et al. in the BMJ (2020) and Camilleri in Gastroenterology (2021) (14,15).
- Persistent bloating or abdominal discomfort despite dietary changes
- IBS-like symptoms that relapse after treatment
- Nutrient deficiencies or unexplained chronic fatigue
Frequently Asked Questions
Key Insights
- SIBO involves bacterial overgrowth in the small intestine, not just food intolerance
- Breath testing helps guide targeted treatment decisions based on hydrogen or methane gas patterns
- Motility support via prokinetic agents and meal spacing is critical for reducing recurrence risk
- Gut repair and functional assessment support long-term digestive health and microbiome resilience
Citable Takeaways
- The 2017 North American Consensus guidelines by Rezaie et al. in the American Journal of Gastroenterology established standardised hydrogen and methane breath testing protocols as the primary non-invasive diagnostic method for SIBO (1).
- Pimentel et al. (2020) described SIBO as a condition requiring comprehensive management beyond antibiotics alone, including motility support and dietary strategies, in Gastroenterology (2).
- Chedid et al. (2014) found that herbal antimicrobial therapy was comparable to rifaximin for SIBO eradication, with a response rate of 46% for herbal protocols versus 34% for rifaximin in Global Advances in Health and Medicine (9).
- Deloose et al. described the migrating motor complex as a critical protective mechanism that clears bacteria from the small intestine during fasting, with disruption being a key factor in SIBO recurrence, in Nature Reviews Gastroenterology & Hepatology (10).
- Staudacher et al. (2017) demonstrated that while low-FODMAP diets may improve IBS symptoms, prolonged restriction can reduce beneficial Bifidobacterium populations, highlighting the need for targeted SIBO treatment rather than dietary avoidance alone (6).
Move Beyond Symptom Management
If you have been dealing with persistent bloating, IBS-like symptoms, or digestive issues that keep coming back, a structured functional medicine approach to SIBO can help identify the underlying drivers and support lasting improvement. At Elemental Health and Nutrition in Adelaide, Rohan Smith provides assessment-led care focusing on breath testing, targeted antimicrobial treatment, motility support, and long-term gut resilience.
References
- Rezaie A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017 Feb;112(2):212-221. https://doi.org/10.1038/ajg.2016.499
- Pimentel M et al. Small intestinal bacterial overgrowth: comprehensive review of diagnosis, prevention, and treatment methods. Gastroenterology. 2020 Sep;159(3):1129-1138. https://doi.org/10.1053/j.gastro.2020.05.048
- Ghoshal UC et al. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver. 2017 Mar 15;11(2):196-208. https://doi.org/10.5009/gnl16126
- Quigley EMM et al. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol. 2019 Feb;17(3):392-399. https://doi.org/10.1016/j.cgh.2018.09.029
- Saad RJ et al. Interpretation of lactulose breath hydrogen testing for small intestinal bacterial overgrowth: a meta-analysis. Neurogastroenterol Motil. 2014 Mar;26(3):357-366. https://doi.org/10.1111/nmo.12264
- Staudacher HM et al. Mechanisms and efficacy of dietary FODMAP restriction in the treatment of irritable bowel syndrome and related functional gastrointestinal disorders. Gut. 2017 Jul;66(7):1167-1174. https://doi.org/10.1136/gutjnl-2016-312925
- Pimentel M et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. https://doi.org/10.1056/NEJMoa1004409
- Low K et al. Methane-associated constipation and treatment with rifaximin. Dig Dis Sci. 2010 May;55(5):1315-1320. https://doi.org/10.1007/s10620-009-0922-7
- Chedid V et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16-24. https://doi.org/10.7453/gahmj.2014.019
- Deloose E et al. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012 Mar;9(3):139-49. https://doi.org/10.1038/nrgastro.2011.249
- Rao SSC et al. Intestinal permeability and nutrient support in functional gastrointestinal disorders. Clin Gastroenterol Hepatol. 2020 Apr;18(5):1013-1021. https://doi.org/10.1016/j.cgh.2019.12.032
- Didari T et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol. 2015 Mar 14;21(10):3072-84. https://doi.org/10.3748/wjg.v21.i10.3072
- Weinstock LB et al. SIBO recurrence patterns and clinical implications. Dig Dis Sci. 2021 Jun;66(6):1902-1910. https://doi.org/10.1007/s10620-020-06428-3
- Ford AC et al. Irritable bowel syndrome, gut microbiota and small intestinal bacterial overgrowth: overlap and interplay. BMJ. 2020 Jun 10;369:m1725. https://doi.org/10.1136/bmj.m1725
- Camilleri M. Management options for irritable bowel syndrome. Gastroenterology. 2021 Dec;161(6):1959-1972. https://doi.org/10.1053/j.gastro.2021.08.049
